Treatment and prevention of HIV infection with long-acting antiretrovirals

References

• De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009;33:307–320.
   PubMed Web of Science ®Google Scholar
• INSIGHT STAR Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.
   PubMed Web of Science ®Google Scholar
• Grinzstejn B, Hosseinipour M, Ribaudo H, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes HIV-1 infection: results from the phase 3 HPTN-052 randomized controlled trial. Lancet Infect Dis. 2014;14:281–290.
   PubMed Web of Science ®Google Scholar
• Cihlar T, Fordyce M. Current status and prospects of HIV treatment. Curr Opin Virol. 2016;18:50–56.
   PubMed Web of Science ®Google Scholar
• Samji H, Cescon A, Hogg R, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;88:e81355.
   Google Scholar
• The Antiretroviral Therapy Cohort Collaboration (ART-CC). Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349–e356.
   PubMed Web of Science ®Google Scholar
• Chua J, Kottilil S. Are we nearing the end in the fight against hepatitis C? Expert Rev Gastroenterol Hepatol. 2017;11:499–500.
   PubMed Web of Science ®Google Scholar
• Rodger A, Cambiano V, Bruun T, et al.; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316:171–181.
   PubMed Web of Science ®Google Scholar
• Barreiro P, Duerr A, Beckerman K, et al. Reproductive options for HIV-serodiscordant couples. AIDS Rev. 2006;8:158–170.
   PubMed Web of Science ®Google Scholar
• Barouch D. Challenges in the development of an HIV-1 vaccine. Nature. 2008;455:613–619.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Landovitz R. Pre-exposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep. 2011;8:94–103.
   PubMedGoogle Scholar
• Fernández-Montero JV, Barreiro P, Del Romero J, et al. Antiretroviral drugs for pre-exposure prophylaxis of HIV infection. AIDS Rev. 2012;14:54–61.
   PubMed Web of Science ®Google Scholar
• WHO. Global summary of the AIDS epidemic 2015. Geneva, Switzerland: World health Organization; 2016. Cited 2017 Aug 25. Available from: http://www.who.int/hiv/data/epi_core_july2015
   Google Scholar
• Nachega J, Parienti J, Uthman O, et al. Lower pill burden and once daily dosing antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58:1297–1307.
   PubMed Web of Science ®Google Scholar
• Grant R, Lama J, Anderson P, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2578–2599.
   Web of Science ®Google Scholar
• Baeten J, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.
   PubMed Web of Science ®Google Scholar
• Thigpen M, Kebaabetswe P, Paxton L, et al. Antiretroviral pre-exposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:399–410.
   PubMed Web of Science ®Google Scholar
• Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (The Bangkok Tenofovir study): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381:2083–2090.
   PubMed Web of Science ®Google Scholar
• McComarck S, Dunn D, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60.
   PubMed Web of Science ®Google Scholar
• Lederman M, Cannon P, Currier J, et al. A cure for HIV infection: “Not in my lifetime” or “Just around the corner”? Pathog Immun. 2016;1:154–164.
   PubMedGoogle Scholar
• O’Connor J, Smith C, Lampe F, et al. UK Collaborative HIV Cohort (CHIC) Study. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV. 2017;4:e295–e302.
   PubMed Web of Science ®Google Scholar
• Dharan N, Cooper D. Long-term durability of HIV viral load suppression. Lancet HIV. 2017;4:e279–e280.
   PubMed Web of Science ®Google Scholar
• Gill V, Lima V, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis. 2010;50:98–105.
   PubMed Web of Science ®Google Scholar
• Clutter D, Jordan M, Bertagnolio S, et al. HIV drug resistance and resistance testing. Infect Genet Evol. 2016;46:292–307.
   PubMed Web of Science ®Google Scholar
• Pham P. Antiretroviral adherence and pharmacokinetics; review of their roles in sustained virologic suppression. AIDS Patient Care STDs. 2009;23:803–807.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.
   PubMed Web of Science ®Google Scholar
• Traverso G, Langer R. Perspective: special delivery for the gut. Nature. 2015;519:19.
   PubMed Web of Science ®Google Scholar
• Amico K, Mansoor L, Corneli A, et al. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17:2143–2155.
   PubMed Web of Science ®Google Scholar
• Hickey M, Merisko-Liversidge E, Remenar J, et al. Delivery of long acting injectable antivirals: best approaches and recent advances. Curr Opin Infect Dis. 2015;28:603–610.
   PubMed Web of Science ®Google Scholar
• Edagwa B, McMillan J, Sillman B, et al. Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv. 2017;14:1281–1291.
   Web of Science ®Google Scholar
• Weiden P, Schooler N, Weedon J, et al. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry. 2009;70:1397–1406.
   PubMed Web of Science ®Google Scholar
• Hubacher D, Spector H, Monteith C, et al. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial. Am J Obstet Gynecol. 2017;216:101–109.
   PubMed Web of Science ®Google Scholar
• Sethi A, Celentano D, Gange S, et al. Association between adherence to antiretroviral therapy and HIV drug resistance. Clin Infect Dis. 2003;37:1112–1118.
   PubMed Web of Science ®Google Scholar
• Landovitz R, Kofron R, McCauley M, et al. The promise and pitfalls of long-acting injectable agents for HIV prevention. Curr Opin HIV/AIDS. 2016;11:122–128.
   PubMed Web of Science ®Google Scholar
• Baert L, Van´T Klooster G, Dries W, et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TCM287) for HIV treatment. Eur J Pharm Biopharm. 2009;72:502–508.
   PubMed Web of Science ®Google Scholar
• Whitfield T, Torkington A, Halsema C. Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. HIV/AIDS. 2016;14:157–168.
   Google Scholar
• Landovitz R, Grinsztejn B. Long-acting injectable pre-exposure prophylaxis for HIV prevention in South Africa: is there a will and a way? J Infect Dis. 2016;213:1519–1520.
   PubMed Web of Science ®Google Scholar
• Trezza C, Ford S, Spreen W, et al. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV/AIDS. 2015;10:239–245.
   PubMed Web of Science ®Google Scholar
• Spreen W, Margolis D, Pottage J. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV/AIDS. 2013;8:565–571.
   PubMed Web of Science ®Google Scholar
• McCormack S, Boffito M. Long-acting cabotegravir for prevention: hope versus reality. Lancet HIV. 2017;4:e322–e323.
   PubMed Web of Science ®Google Scholar
• Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agent Chemother. 2010;54:718–727.
   PubMed Web of Science ®Google Scholar
• Garvey L, Winston A. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs. 2009;18:1035–1041.
   PubMed Web of Science ®Google Scholar
• Jackson A, McGowan I. Long-acting rilpivirine for HIV prevention. Curr Opin HIV-AIDS. 2015;10:253–257.
   PubMed Web of Science ®Google Scholar
• Wilkin A, Pozniak A, Morales-Ramirez J, et al. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretrovirals naïve patients: week 192 results from a phase IIb randomized trials. AIDS Res Hum Retroviruses. 2012;28:437–446.
   PubMed Web of Science ®Google Scholar
• Margolis D, Brinson C, Smith G, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naïve-adults with HIV-1 infection (LATTE): a randomized, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15:1145–1155.
   PubMed Web of Science ®Google Scholar
• Spreen W, Min S, Ford S, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials. 2013;14:192–203.
   PubMed Web of Science ®Google Scholar
• Andrews S, Spreen W, Mohri H, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343:1151–1154.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Frank I, Grant R, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomized, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331–e340.
   PubMed Web of Science ®Google Scholar
• Margolis D, Gonzalez-Garcia J, Stellbrink H, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390:1499–1510.
   Web of Science ®Google Scholar
• Nguyen B, Jensen J. Evaluating the efficacy and safety of a progestin- and estrogen-releasing ethylene vinyl acetate copolymer contraceptive vaginal ring. Expert Opin Drug Saf. 2014;13:1423–1430.
   PubMed Web of Science ®Google Scholar
• Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised, controlled trial. Lancet. 2002;360:962–964.
   PubMed Web of Science ®Google Scholar
• Devlin B. Development of dapivirine vaginal ring for HIV prevention. Antiviral Res. 2013;100(suppl):3–8.
   PubMed Web of Science ®Google Scholar
• Dezzutti C, Richardson-Harman N, Rohan L, et al.; Microbicide Trials Network, MTN-013IPM 026 Protocol Team. Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial. Medicine (Baltimore). 2016;95:e4174.
   PubMed Web of Science ®Google Scholar
• Giacobbi N, Sluis-Cremer N. In vitro cross-resistance profiles of rilpivirine, dapivirine and MIV-150: NNRTI microbicides in clinical development for the prevention of HIV-1 infection. Antimicrob Agents Chemother. 2017;61:e00277–17.
   PubMed Web of Science ®Google Scholar
• Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689–696.
   PubMed Web of Science ®Google Scholar
• Barrios A, García-Benayas T, González-Lahoz J, et al. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS. 2004;18:960–963.
   PubMed Web of Science ®Google Scholar
• Bedimo R, Maalouf N, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825–831.
   PubMed Web of Science ®Google Scholar
• Raffi F, Orkin C, Clarke A, et al. Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. J Acquir Immune Defic Syndr. 2017;75:226–231.
   PubMed Web of Science ®Google Scholar
• Mandal S, Prathipati P, Kang G, et al. Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission. AIDS. 2017;31:469–476.
   PubMed Web of Science ®Google Scholar
• Gunawardana M, Remedios-Chan M, Miller C, et al. Pharmacokinetics of long acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob Agents Chemother. 2015;59:3913–3919.
   PubMed Web of Science ®Google Scholar
• Friedman E, Schuermann D, Rudd D, et al. A single monotherapy dose of MK-8591, a novel NRTI, suppresses HIV for 10 days, CROI. San Francisco, CA: IAS-USA Editors; 2016. Abstract 437LB.
   Google Scholar
• Guo D, Zhou T, Araínga M, et al. Creation of a long-acting nanoformulated 2ʹ,3ʹ-dideoxy-3ʹ-thiacytidine. J Acquir Immune Defic Syndr. 2017;74:e75–e83.
   PubMed Web of Science ®Google Scholar
• Mandal S, Belshan M, Holec A, et al. An enhanced emtricitabine-loaded long-acting nanoformulation for prevention or treatment of HIV infection. Antimicrob Agents Chemother. 2017;61:e01475–16.
   PubMed Web of Science ®Google Scholar
• Caskey M, Klein F, Lorenzi J, et al. Viremia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522:487–491.
   PubMed Web of Science ®Google Scholar
• Lynch R, Boritz E, Coates E, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015;7:319ra206.
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Flexner C. Universal antiretroviral regimens: thinking beyond one-pill-once-a-day. Curr Opin HIV/AIDS. 2017;12:343–350.
   PubMed Web of Science ®Google Scholar
• Quinn K, Traboni C, Penchala S, et al. A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol. Sci Rep. 2017;7:9447.
   PubMed Web of Science ®Google Scholar
• Grant R, Anderson P, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet. 2014;14:820–829.
   PubMed Web of Science ®Google Scholar
• Molina JM, Capitant C, Spire B, et al. ANRS IPERGAY Study Group. On-demand pre-exposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237–2246.
   PubMed Web of Science ®Google Scholar
• Hendrix C. Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design. Cell. 2013;155:515–518.
   PubMed Web of Science ®Google Scholar
• Knox D, Anderson P, Harrigan P, et al. Multidrug-resistant HIV-1 infection despite pre-exposure prophylaxis. N Engl J Med. 2017;376:501–502.
   PubMed Web of Science ®Google Scholar
• Soriano V. Transmission of multi-drug resistant HIV-1 despite antiretroviral prophylaxis. AIDS Rev. 2017;19:54–55.
   PubMed Web of Science ®Google Scholar
• Van Damme L, Corneli A, Ahmend K, et al. Pre-exposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–422.
   PubMed Web of Science ®Google Scholar
• Marrazzo J, Ramjee G, Richardson B. Tenofovir-based pre-exposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–518.
   PubMed Web of Science ®Google Scholar
• Eisingerich A, Wheelock A, Gomez G, et al. Attitudes and acceptance of oral and parenteral HIV pre-exposure prophylaxis among potential users groups: a multinational study. PLoS One. 2012;7:e28238.
   PubMed Web of Science ®Google Scholar
• Meyers K, Rodriguez K, Moeller R, et al. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: A P18 cohort substudy. PLoS One. 2014;9:e114700.
   PubMed Web of Science ®Google Scholar
• Wheelock A, Eisingerich A, Ananworanich J, et al. Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. PLoS One. 2013;8:e54288.
   PubMed Web of Science ®Google Scholar
• McGowan I, Dezzutti C, Siegel A, et al. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. Lancet HIV. 2016;3:e569–e578.
   PubMed Web of Science ®Google Scholar
• Bekker L, Li S, Tolley B. HPTN 076: TMC278 LA safe, tolerable, and acceptable for HIV pre-exposure prophylaxis. CROI 2017; Feb 13-16; Seattle (WA); 2017. Abstract 421LB.
   Google Scholar
• Radzio J, Spreen W, Yueh Y, et al. The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med. 2015;7:270ra5.
   PubMed Web of Science ®Google Scholar
• Andrews C, Bernard L, Poon A, et al. Cabotegravir long-acting injections protects macaques against intravenous challenge. CROI; Feb; Boston (MA); 2016. Abstract 105.
   Google Scholar
• HPTN077. A phase IIa study to evaluate the safety, tolerability and pharmacokinetics of the investigational injectable HIV integrase inhibitor, GSK 1265744, in HIV-uninfected men and women. Study protocol final version 2.0.IND #122744. DAIDS Document ID: 11964. [cited 2017 Aug 26]. Available from: https://www.htpn.org/research/studies/153
   Google Scholar
• Sugarman J. Ethical considerations regarding oral pre-exposure prophylaxis in HIV prevention trials. Curr Opin HIV/AIDS. 2016;11:109–115.
   PubMed Web of Science ®Google Scholar
• Baeten JM, Palanee-Phillips T, Brown E, et al.; MTN-020–ASPIRE Study Team. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121–2132.
   PubMed Web of Science ®Google Scholar
• Montgomery E, van der Straten A, Chitukuta M, et al.; MTN-020/ASPIRE Study. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31:1159–1167.
   PubMed Web of Science ®Google Scholar
• Nel A, van Niekerk N, Kapiga S, et al.; Ring Study Team. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133–2143.
   PubMed Web of Science ®Google Scholar
• Ruane P, De Jesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquire Immune Defic Syndr. 2013;63:449–455.
   PubMed Web of Science ®Google Scholar
• Kirtane A, Langer R, Traverso G. Progress in formulation-based approaches for antiretrovirals. J Pharm Sci. 2016;105:3471–3482.
   PubMedGoogle Scholar
• Soriano V, Fernandez-Montero JV, Benitez L, et al. Dual antiretroviral therapy for HIV infection. Exp Op Drug Saf. 2017;16:923–932.
   PubMed Web of Science ®Google Scholar
• Stellbrink H, Reynes J, Lazzarin A, et al. Dolutegravir in antiretroviral-naïve adults with HIV-1: 96 weeks results from a randomized dose ranging study. AIDS. 2013;27:1771–1778.
   PubMed Web of Science ®Google Scholar
• Walmsley S, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV infection. N Engl J Med. 2013;369:1807–1818.
   PubMed Web of Science ®Google Scholar
• Spreen W, Williams P, Margolis D, et al. Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TCM278) long-acting nanosuspension in healthy adults. J Acquir Immune Defic Syndr. 2014;67:487–492.
   PubMed Web of Science ®Google Scholar
• Spreen W, Ford S, Chen S, et al. GSK1265744 pharmacokinetics in plasma and tissue after a single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr. 2014;67:481–486.
   PubMed Web of Science ®Google Scholar
• Zhang S, Bellinger A, Glettig D, et al. A pH-responsive supramolecular polymer gel as an enteric elastomer for use in gastric devices. Nat Mater. 2015;14:1065–1071.
   PubMed Web of Science ®Google Scholar
• Klausner E, Lavy E, Friedman M, et al. Expandable gastro-retentive dosage forms. J Control Release. 2003;90:143–162.
   PubMed Web of Science ®Google Scholar
• Rusconi S, Marcotullio S, Cingolani A. Long-acting agent for HIV infection: biological aspects, role in treatment and prevention, and patient´s perspective. New Microbiol. 2017;40:75–79.
   PubMed Web of Science ®Google Scholar
• Jackson A, Else L, Mesquita P, et al. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharmacol Ther. 2014;96:314–323.
   PubMed Web of Science ®Google Scholar
• Penrose K, Parikh U, Hamanishi K, et al. Selection of rilpivirine-resistant HIV-1 in a seroconverter from the SSAT 040 trial who received the 300-mg doses of long-acting rilpivirine (TMC278LA). J Infect Dis. 2016;213:1013–1017.
   PubMed Web of Science ®Google Scholar
• Arya V, Au S, Belew Y, et al. Regulatory challenges in developing long-acting antiretrovirals for treatment and prevention of HIV infection. Curr Opin HIV/AIDS. 2015;10:278–281.
   PubMed Web of Science ®Google Scholar
• Iwuji C, Newell M. Towards control of the global HIV epidemic: addressing the middle-90 challenge in the UNAIDS 90- 90-90target. PLoS Med. 2017;14:e1002293.
   PubMed Web of Science ®Google Scholar
• Altice F, Kamarulzaman A, Soriano V, et al. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376:367–387.
   PubMed Web of Science ®Google Scholar
• Chibanda D, Benjamin L, Weiss H, et al. Mental, neurological, and substance use disorders in people living with HIV/AIDS in low- and middle-income countries. J Acquir Immune Defic Syndr. 2014;67(suppl 1):54–67.
   PubMed Web of Science ®Google Scholar
• Brinkley-Rubinstein L, Rosen D, Christopher P, et al. Long-acting injectable antiretroviral therapy: an opportunity to improve HIV treatment and reduce HIV transmission among persons being released from prison facilities. Clin Infect Dis Forthcoming.
   Web of Science ®Google Scholar
• Nyberg C, Patterson B, Williams M. When patients cannot take pills: antiretroviral drug formulations for managing adult HIV infection. Top Antivir Med. 2011;19:126–131.
   PubMedGoogle Scholar
• Barnhart M. Long acting HIV treatment and prevention: closer to the threshold. Glob Health Sci Pract. 2017;5:182–187.
   PubMed Web of Science ®Google Scholar
• Tse W, Link J, Mulato M, et al. Discovery of novel potent HIV capsid inhibitors with long-acting potential. 24th CROI; Feb 13-17; Seattle (WA); 2017. [abstract 38].
   Google Scholar
• Matthews R, Schürmann D, Rudd D, et al. Single doses as low as 0.5 mg of the novel NRTTI MK-8591 suppress HIV for at least seven days. 9th IAS Conference; Jul 23-26; Paris; 2017. [abstract TUPDB020].
   Google Scholar
• Markowitz M, Gettie A, St. Bernard L, et al. Weekly oral MK-8591 protects male rhesus macaques against repeated low dose intrarectal challenge with SHIV109CP3. 9th IAS Conference; Jul 23-26; Paris; 2017. [abstract MOAX0203LB].
   Google Scholar
• Rademacher K, Solomon M, Brett T, et al. Expanding access to a new, more affordable levonorgestrel intrauterine system in Kenya: service delivery costs compared with other contraceptive methods and perspectives of key opinion leaders. Glob Health Sci Pract. 2016;4(suppl 2):83–93.
   Google Scholar
• Schlesinger E, Johengen D, Luecke E, et al. A tunable, biodegradable, thin-film polymer device as a long-acting implant delivering tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis. Pharm Res. 2016;33:1649–1656.
   PubMed Web of Science ®Google Scholar
• Chua C, Jain P, Hu M, et al. Transcutaneous refillable nanofluidic implant for constant delivery of HIV PrEP. 24th CROI; Feb 13-17; Seattle, WA; 2017. [abstract 422LB].
   Google Scholar
• Kirtane A, Abouzid O, Minahan D, et al. Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy. Nat Commun. 2018;9:2.
   PubMed Web of Science ®Google Scholar